Evaluating statins for treating Moyamoya disease
Official title: Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease
Run by Beijing Tiantan Hospital · NCT06817434 · Data updated 2026-11-12
This study is testing if statin medication can help improve the condition and outcomes for people with Moyamoya disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 330 (estimated) |
| Sponsor | Beijing Tiantan Hospital Academic / other |
| Locations | 1 site (Beijing, China) |
| Status | Recruiting |
| Started | December 15, 2024 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | February 10, 2025 |
| Trial ID | NCT06817434 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older diagnosed with Moyamoya disease who meet specific imaging and clinical criteria.
✕Probably not a fit
Patients with conditions such as atherosclerosis, autoimmune diseases, or those under 18 years old may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effectiveness of statins in treating Moyamoya disease using multimodal magnetic resonance imaging. It involves patients who have been diagnosed with the condition and are receiving either revascularization or conservative management. The study aims to assess the impact of statin therapy on disease progression and patient outcomes through imaging follow-ups.
Why it matters
Potential benefit: If successful, this study could provide new insights into the management of Moyamoya disease and improve treatment options for patients.
How similar studies have gone: While the use of statins in cerebrovascular diseases has been explored, this specific application in Moyamoya disease is relatively novel and not extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The imaging examination meets the diagnostic criteria for moyamoya disease; 2. Sign the informed consent form; 3. Age ≥18 years old; 4. Baseline mRS score ≤2 points; 5. The patient receives revascularization/conservative treatment; 6. There is at least 1 imaging follow-up result. Exclusion Criteria: 1. Patients with atherosclerosis, autoimmune diseases, meningitis, Down syndrome, cranial trauma, or those who have undergone radioactive head irradiation, as these conditions may lead to secondary cerebrovascular disease and contribute to the development of Moyamoya syndrome; 2. Individuals under the age of 18; 3. Participants who refuse to take part in this study; 4. Pregnant patients; 5. Those with concurrent intracranial aneurysms, cerebrovascular malformations, brain tumors, or hydrocephalus; 6. A history of stroke occurring more than three months prior to the diagnosis of Moyamoya disease; 7. Individuals with a history of coronary heart disease or previous cardiovascular and cerebrovascular surgical interventions, including cerebral revascularization, intracranial artery stent implantation, carotid artery stenting, endarterectomy, coronary artery bypass grafting, or coronary stent implantation; 8. Allergies to contrast media; 9. Patients with missing imaging data or whose image quality cannot be analyzed; 10. Individuals who refuse or are unable to undergo imaging follow-up; 11. Patients receiving other types of lipid-lowering drug treatments.
Where it's running
-
Beijing Tiantan Hospital
Beijing, China, China Recruiting
Study contacts
- Study coordinator: Qian Zhang
- Email: zhangqianchina@yahoo.com
- Phone: 8613120012579
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Risk prediction for stroke and cognitive decline in Moyamoya disease and Moyamoya syndrome
A large multicenter study tests whether combining clinical data, imaging, lab and genetic information can predict who will have stroke or cognitive decline among people with Moyamoya.
-
5T MRI and Metabolomics to Predict Hemorrhage Risk in Moyamoya Disease
This study tests whether advanced 5T MRI imaging and metabolomics can help predict which moyamoya patients are at higher risk of intracranial hemorrhage.
-
XR-assisted CT-guided localization for EC-IC bypass in Moyamoya and chronic cerebral ischemia
The study tests whether a metaverse-based surgical simulation with extended reality helps localize vessels during EC-IC bypass for moyamoya disease or chronic cerebral ischemia.
-
Family screening and early detection for moyamoya disease
This project will try to find biological signs and 5T high-resolution MRI features that could detect moyamoya earlier in people with the disease, their first-degree relatives, and people without a family history.
-
Remimazolam: target-controlled infusion versus manual infusion during cerebrovascular bypass
This trial will test whether target-controlled infusion uses less remimazolam than manual infusion in adults undergoing cerebrovascular bypass surgery for moyamoya disease.
-
Cardiac index–guided blood flow management during pediatric Moyamoya EDAS surgery
This study will test whether using each child's cardiac index to guide fluids and hemodynamic care during EDAS lowers postoperative transient ischemic episodes in children with Moyamoya disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.